knowledge -WSS

knowledge

author：Wikipedia 2025-09-29 21:25:25 - browse：51133

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Listen: More tumult at BIO & coercive care for sickle cell patients

focus

WSS

Sanofi strikes deal with Novavax, boosting the vaccine maker

Brain worms: The science behind RFK Jr.'s parasitic infection

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Biogen joins immunology wave with $1.15 billion acquisition of HI

H5N1 bird flu outbreak: Second human case reported, in Michigan

hotspot

knowledge

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Apple is now the first public company to be valued at $3 trillion

FDA poised to publish guidelines for clinical trial diversity

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

What does generative AI mean for health care? We asked experts

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Heart attack and stroke risk calculators need revising

Investigation reveals sickle cell patients pressured into sterilizations

hotspot

Liver decline slowed by off

For longer

Fentanyl is making it harder to start addiction treatment

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Dairy farmers resist CDC push for PPE against bird flu virus

Software glitch causes Tandem insulin pump to shutdown, FDA warns

focus

focus

focus

knowledge